From the Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, China (Yang, Zhang).
From the Department of Pathology, Peking University People's Hospital, Beijing, China (Liu, Yan, Shen).
Arch Pathol Lab Med. 2022 Jun 1;146(6):735-741. doi: 10.5858/arpa.2021-0153-OA.
CONTEXT.—: Tumors harboring CIC-NUTM1 fusion are a newly recognized rare sarcoma, but the documented cases are still limited. It is unclear whether it is the same as classic CIC-DUX4 sarcoma in terms of its clinical, pathologic, and behavioral aspects.
OBJECTIVE.—: To further explore the clinicopathologic characteristics of CIC-NUTM1 sarcoma.
DESIGN.—: The cases were diagnosed based on immunophenotype, next-generation sequencing, and fluorescence in situ hybridization tests and compared with the reported CIC-NUTM1 sarcomas in the literature.
RESULTS.—: Three cases of CIC-NUTM1 sarcomas involving the spine in adults were described. The tumors occurred in 2 men and 1 woman, aged 38 to 61 years. Two tumors were located in thoracic vertebrae and 1 in a cervical vertebra. All were locally advanced lesions destroying the bone and soft tissues without spinal cord involvement or metastasis. The tumors were composed of monomorphic small to medium-sized cells with round to epithelioid appearance. The architecture was lobulated and solid with diffuse or multifocal myxoid stroma. Next-generation sequencing revealed an in-frame fusion between CIC (exon 16 or 17) and NUTM1 (exon 5 or 6) in 3 cases. Fluorescence in situ hybridization confirmed CIC and NUTM1 breaks, and immunohistochemistry showed NUT staining in the nucleus. The patients died of disease 8 to 15 months (mean, 10.7 months) after presentation. Of the CIC-NUTM1 sarcomas reported in the literature along with our cases (n = 11), 8 cases developed in axial bone (5 spine, 3 skull base).
CONCLUSIONS.—: CIC-NUTM1 sarcomas demonstrate distinct anatomic tropism for the axial skeleton and unfavorable behavior compared with classic CIC sarcoma.
携带 CIC-NUTM1 融合的肿瘤是一种新认识的罕见肉瘤,但已记录的病例仍然有限。目前尚不清楚其在临床、病理和行为方面与经典的 CIC-DUX4 肉瘤是否相同。
进一步探讨 CIC-NUTM1 肉瘤的临床病理特征。
根据免疫表型、下一代测序和荧光原位杂交试验进行诊断,并与文献中报道的 CIC-NUTM1 肉瘤进行比较。
描述了 3 例成人脊柱 CIC-NUTM1 肉瘤病例。肿瘤发生于 2 名男性和 1 名女性,年龄 38 岁至 61 岁。2 个肿瘤位于胸椎,1 个位于颈椎。所有肿瘤均为局部晚期病变,破坏骨骼和软组织,无脊髓受累或转移。肿瘤由形态单一的小至中等大小的圆形至上皮样细胞组成。肿瘤结构呈分叶状和实性,伴弥漫性或多灶性黏液样基质。下一代测序显示 3 例均存在 CIC(外显子 16 或 17)与 NUTM1(外显子 5 或 6)的融合。荧光原位杂交证实了 CIC 和 NUTM1 的断裂,免疫组化显示核内 NUT 染色。患者在出现症状后 8 至 15 个月(平均 10.7 个月)内死于疾病。与文献中报道的 CIC-NUTM1 肉瘤病例(n=11)和我们的病例一起(n=11),8 例发生在轴性骨(5 例脊柱,3 例颅底)。
与经典的 CIC 肉瘤相比,CIC-NUTM1 肉瘤在轴向骨骼上具有明显的解剖倾向和不良的行为。